Who are SNG001's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Peginterferon Alfa, Thymosin alpha1 & Pegylated Interferon-alpha2a, PegIFN-2b, Rebif® (clone 484-39), Pegintron + Riba, Pegylated interferon alpha 2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sng001.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SNG001 — Competitive Intelligence Brief

SNG001 (SNG001) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Respiratory.

phase 3 Interferon IFNAR Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

SNG001 (SNG001) — Synairgen Research Ltd.. SNG001 is an inhaled interferon beta-1a, which works by stimulating the body's immune response to fight off respiratory viruses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SNG001 TARGET	SNG001	Synairgen Research Ltd.	phase 3	Interferon	IFNAR
Peginterferon Alfa	Peginterferon Alfa	Third Affiliated Hospital, Sun Yat-Sen University	marketed	Interferon-alpha	Interferon-alpha receptor (IFNAR)
Thymosin alpha1 & Pegylated Interferon-alpha2a	Thymosin alpha1 & Pegylated Interferon-alpha2a	Seoul National University Hospital	marketed	Immunomodulator combination	T-cell maturation pathway; interferon-alpha receptor (IFNAR)
PegIFN-2b	PegIFN-2b	Merck Sharp & Dohme LLC	marketed	Pegylated interferon-beta	Interferon-beta receptor (IFNAR)
Rebif® (clone 484-39)	Rebif® (clone 484-39)	Merck KGaA, Darmstadt, Germany	marketed	Interferon beta-1a	Type I interferon receptor (IFNAR)
Pegintron + Riba	Pegintron + Riba	Chang Gung Memorial Hospital	marketed	Antiviral combination therapy (interferon + nucleoside analog)	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Pegylated interferon alpha 2	Pegylated interferon alpha 2	Ain Shams University	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

EMD Serono · 3 drugs in this class
Cinnagen · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
Case Comprehensive Cancer Center · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Human Genome Sciences Inc. · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SNG001 — Competitive Intelligence Brief. https://druglandscape.com/ci/sng001. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab